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– 556,900 American will die of cancer this year 
–1,372,900 Americans will be diagnosed with cancer this year 
Burden of Cancer 
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• Combine power of innovation in nano-materials and 
cancer biology to develop new solutions in cancer 
•  Detect Disease Before Health Has Deteriorated 
– Sensors 
– Imaging  
•   Deliver Therapeutics 
– Local delivery 
– Improved efficacy 
– Post-therapy monitoring 
• Develop Research Tools to Enhance Understanding of 
the Disease 
Cancer Nanotechnology: 
The Opportunity 
Liposome Gold nanoshell Quantum Dot Dendrimer 
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• In-vitro assays 
• High sensitivity 
• Development of modular diagnostics based on bodily fluids, such as 
blood, serum, cerebrospinal, urine, stools, or saliva 
• Techniques to monitor and capture circulating tumor cells from blood 
• Multiplexing – capability to monitor several signatures at the same time 
• Multifunctional capabilities – one platform capable of detecting nucleic 
acids and proteins 
• Imaging 
• Improved spatial and temporal resolution 
• Capability to probe tumor microenvironment – information on tumor 
mass and its biochemical signatures  
• Theranostic constructs allow for tumor recognition and subsequent 
treatment – image-guided therapy 
• Intra-operative techniques to monitor margins of surgically removed 
tissue in real-time 
Early Diagnosis and Post-therapy Monitoring 
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Hyperthermia 
N. Halas, J. West et al,  
Ann Biomed Eng.  
(2006) 34: 15 
Delivery of chemotherapeutics 
J. Baker, et al., Cancer Res. 
(2005) 65 : 5317 
Pro-drug strategy 
Genetic therapy 
Nano-therapy Strategies 
A. Ito et al., J. of 
Bioscience and Bioeng. 
(2005 100: 1) 
Liposome 
Magnetite nanoparticle 
Photothermal                 RF heated 
M. Davis et al. Nature (2010) 464: 1067 
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Pro-drug Strategies 
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NCI Alliance for Nanotechnology in  
Cancer (ANC) - Program Objectives 
   The ANC program was designed to develop research capabilities 
   for multi-disciplinary team research, with the goal of  advancing 
   prevention, diagnostic and/or treatment efforts.  
 
 
 
 
 
 
 
 
 
 
Challenge areas: 
 
• Early diagnosis using in vitro assays and  
    devices or in vivo imaging techniques 
• Multifunctional nano-therapeutics and  
    post-therapy monitoring tools 
• Devices and techniques for  cancer 
    prevention and control 
 
 
 
 
The ANC’s development model 
calls for the most promising 
strategies discovered and 
developed by ANC grantees to 
be handed off to for-profit 
partners for effective clinical 
translation and commercial 
development. 
 
Focus on cancers with low 
survival rates such as brain, 
lung, pancreas, and ovarian 
cancer 
 
research discovery 
pre-clinical 
clinical 
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5 year Survival for Different Cancers 
Rationale Behind Tumor Type Selection 
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0% 
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 
 
Focus program on cancers with low survival rates such as brain, lung, 
pancreas, and ovarian cancer. These were also first four cancers 
sequenced by TCGA. 
 
P
ro
s
ta
te
 
M
e
la
n
o
m
a
 
B
re
a
s
t 
C
o
lo
n
 
O
v
a
ry
 
B
ra
in
 
L
u
n
g
 
P
a
n
c
re
a
s
  
G
B
M
 
 
8 
9 
Translating to the Clinic 
• Value proposition of nanotechnology in cancer – why would 
oncologist care? 
•  defining compelling applications 
• Building research community 
• Discovery research OK, but we want to benefit the patient - 
translate 
 
• Translation is hard and expensive 
•  it costs ~$2M to scale-up and stabilize materials manufacturing to be 
ready for IND application 
•  limited capital available before reaching clinical trial stage – infamous 
‘valley-of-death’ for start-up companies 
• re-defining roles of academia, industry, and government in the 
continuum of funding and performing technology development 
•  engaging larger pharmaceutical and biotech companies 
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Current Industry Trends in R&D 
Development and Commercialization 
Target Identification 
and 
Validation 
Lead Development 
Animal 
Studies 
Clinical 
Trials 
 
Outsourcing, In- and out-licensing  
Mergers & Acquisitions 
Biotech Academia Pharma 
Pharma/ Biotech 
Patient 
Care 
Approval 
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NCI Nanotechnology Alliance 
Commercial Partners 
Stanford CCNE 
Endra, Inc. 
ImaginAb 
MagArray 
Nodality, Inc. 
Zymera 
CellSight 
Technologie 
Nvigen, Inc. 
Stanford CCNE 
General Electric 
Caltech/UCLA CCNE 
Homestead Clinical 
Caltech/UCLA CCNE 
Calando Pharmaceuticals 
Insert Pharmaceuticals 
Calhoun Vision 
CellFluidics 
Intergrated Diagnostics 
Materia 
Molecular Biomarkers 
  
Rice University CNPP 
Nanospectra Biosciences 
Texas CCNE 
AM Biotechnologies, LLC 
Arrowhead Research 
BioPath Holdings, Inc. 
Leonardo Biosystems 
Mercator Therapeutics 
NanoMedical Systems 
Stanford CCNE 
Visual Sonics 
Johns Hopkins CCNE 
MDxHealth 
Johns Hopkins CCNE 
SignPath Pharmaceuticals 
Cancer Imaging Systems, Inc. 
Principio, Inc. 
University of Cincinnati 
Kylin Therapeutics, Inc. 
Cedars-Sinai CNPP 
Arrogene, Inc. 
Emory University CNPP 
Ocean Nanotech 
Northwestern CNPP 
Valence Therapeutics 
Tactic Pharma 
MIT/Harvard CCNE 
Alnylam Pharmaceuticals 
BIND Biosciences 
Lumicell Diagnostics 
MicroCHIPS, Inc. 
T2 Biosystems 
Tempo Pharmaceuticals 
VisEn Medicinal 
Johns Hopkins CCNE 
SurModics Pharmaceuticals 
Northwestern CCNE 
American Bio-Optics 
Aurasense 
Grzybowski Scientific Inventions 
NanoInk, Inc. 
Nanosphere, Inc. 
Nanotope, Inc. 
Ohmx Corporation 
Pharocore 
PreDx, Corporation 
SAMDITech, Inc. 
Dartmouth CCNE 
Adimab, Inc. 
UNC CCNE 
Liquidia, Inc. 
XinRay Systems 
Xintek 
B3 Biosciences 
Qualiber, Inc. 
Nanomed Pharmaceuticals 
Caltech/UCLA 
 
MIT/Harvard 
 
Northwestern University 
 
Stanford University 
 
University of North Carolina 
Dartmouth College 
 
Johns Hopkins University 
 
Northeastern University 
 
University of Texas 
 
CNPPs 
Dartmouth CCNE 
Aspen MediSys 
Philips Healthcare 
UNC CCNE 
Hologic, Inc. 
NanoMed Pharma 
Northeastern CCNE 
Nemucore Medical Innovations 
NovaBioMed, Inc. 
SoluBest (Isreal) 
Johns Hopkins CCNE 
Immune Design Corporation 
Stanford CCNE 
Enlight Biosciences 
Nine Point Medical 
Panorama 
Johns Hopkins CCNE 
Kala Pharmaceuticals 
Celldex Therapeutics 
Caltech, MIT & NEU 
Cerulean Pharma, Inc. 
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• Abraxane® (albumin-bound paclitaxel, Abraxis BioSciences). FDA approval in 2005 for 
metastatic breast cancer 
• Liposomal: 
– Doxil® (liposomal-PEG doxorubicin; Ortho Biotech/ Schering-Plough). FDA approval 
in 1995 for HIV-related Kaposi’s sarcoma, metastatic breast cancer, metastatic 
ovarian cancer 
– DaunoXome® (liposomal daunorubicin; Gilead Sciences/ Diatos). FDA approval in 
1996 for HIV-related Kaposi’s sarcoma 
– Myocet® (liposomal doxorubicin; Zeneus). FDA approval is pending for metastatic 
breast cancer 
• Polymeric: 
– Genexol-PM® (Methoxy-PEG-poly(D,L-lactide) taxol; Samyang, Korea). Approved 
in S. Korea for metastatic breast cancer. Phase II for pancreatic cancer in the US 
– Oncaspar® (PEG–L-asparaginase; Enzon). FDA approval in 2006 for Acute 
Lymphoblastic Leukemia 
 
 Several companies are close to filing IND applications with FDA for 
nanotechnology products 
Nanotherapeutics Approved for  
Oncological Applications 
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Initiation and planning 
 ’04 
Development of assay cascade 
 ’05 
Receipt of materials 
 ’06 
’07-’08 
’09-’11 
Characterization, SAR studies,  
support of early development 
Near capacity, 
Identifying trends, 
more mature concepts 
 
Nanotechnology Characterization Laboratory: 
Serving the Community 
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Forward Strategies 
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High Impact Cancer  
Nanotechnology Goals 
• Early diagnosis  of cancer  in pre-metastatic stage: 
– point-of-care nano-devices  for broad medical applications including cancer using 
unprocessed bodily fluids, with multiplex capabilities and rapid analysis;  
– diagnostic and post-therapy monitoring nano-devices for interrogation of 
circulating tumor cells;    
• Successful  delivery of therapies based on siRNA  and other difficult 
to deliver molecules;  
• Novel nanoparticle-based chemotherapeutic formulations with lower 
toxicity and higher efficacy; 
• Theranostic constructs for diagnosis and subsequent localized 
therapy; 
• Effective diagnosis and delivery of therapies to brain, ovary, and 
pancreas. 
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